全文获取类型
收费全文 | 4217篇 |
免费 | 273篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 25篇 |
儿科学 | 179篇 |
妇产科学 | 115篇 |
基础医学 | 611篇 |
口腔科学 | 58篇 |
临床医学 | 360篇 |
内科学 | 912篇 |
皮肤病学 | 88篇 |
神经病学 | 516篇 |
特种医学 | 127篇 |
外科学 | 531篇 |
综合类 | 15篇 |
一般理论 | 2篇 |
预防医学 | 272篇 |
眼科学 | 40篇 |
药学 | 306篇 |
中国医学 | 6篇 |
肿瘤学 | 343篇 |
出版年
2024年 | 6篇 |
2023年 | 48篇 |
2022年 | 119篇 |
2021年 | 170篇 |
2020年 | 114篇 |
2019年 | 162篇 |
2018年 | 176篇 |
2017年 | 137篇 |
2016年 | 149篇 |
2015年 | 149篇 |
2014年 | 216篇 |
2013年 | 239篇 |
2012年 | 351篇 |
2011年 | 343篇 |
2010年 | 195篇 |
2009年 | 157篇 |
2008年 | 287篇 |
2007年 | 237篇 |
2006年 | 208篇 |
2005年 | 207篇 |
2004年 | 167篇 |
2003年 | 139篇 |
2002年 | 101篇 |
2001年 | 29篇 |
2000年 | 32篇 |
1999年 | 29篇 |
1998年 | 20篇 |
1997年 | 21篇 |
1996年 | 21篇 |
1995年 | 10篇 |
1994年 | 6篇 |
1993年 | 15篇 |
1992年 | 23篇 |
1991年 | 15篇 |
1990年 | 17篇 |
1988年 | 21篇 |
1987年 | 21篇 |
1986年 | 21篇 |
1985年 | 14篇 |
1984年 | 18篇 |
1983年 | 7篇 |
1982年 | 5篇 |
1980年 | 6篇 |
1979年 | 6篇 |
1978年 | 8篇 |
1977年 | 6篇 |
1974年 | 5篇 |
1972年 | 12篇 |
1970年 | 5篇 |
1967年 | 6篇 |
排序方式: 共有4506条查询结果,搜索用时 15 毫秒
51.
B. Fuentes S. Amaro M. Alonso de Leciñana J.F. Arenillas O. Ayo-Martín M. Castellanos M. Freijo A. García-Pastor M. Gomis M. Gómez Choco E. López-Cancio P. Martínez Sánchez A. Morales E.J. Palacio-Portilla M. Rodríguez-Yáñez J. Roquer T. Segura J. Serena J. Vivancos-Mora 《Neurología (Barcelona, Spain)》2021,36(4):305-323
ObjectiveTo update the Spanish Society of Neurology's guidelines for stroke prevention in patients with type 2 diabetes or prediabetes, analysing the available evidence on the effect of metabolic control and the potential benefit of antidiabetic drugs with known vascular benefits in addition to conventional antidiabetic treatments in stroke prevention.DevelopmentPICO-type questions (Patient, Intervention, Comparison, Outcome) were developed to identify practical issues in the management of stroke patients and to establish specific recommendations for each of them. Subsequently, we conducted systematic reviews of the PubMed database and selected those randomised clinical trials evaluating stroke as an independent variable (primary or secondary). Finally, for each of the PICO questions we developed a meta-analysis to support the final recommendations.ConclusionsWhile there is no evidence that metabolic control reduces the risk of stroke, some families of antidiabetic drugs with vascular benefits have been shown to reduce these effects when added to conventional treatments, both in the field of primary prevention in patients presenting type 2 diabetes and high vascular risk or established atherosclerosis (GLP-1 agonists) and in secondary stroke prevention in patients with type 2 diabetes or prediabetes (pioglitazone). 相似文献
52.
53.
54.
55.
56.
57.
58.
Gliddon et al. conducted a randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy of the angiotensin-converting enzyme inhibitor quinapril for the management of vascular damage in systemic sclerosis (SSc). The trial comprised 213 patients with limited cutaneous SSc or Raynaud's phenomenon (mean age 54 years, 182 females) who were randomly assigned to receive 80 mg/day, or the maximum tolerated dose, of quinapril (n = 105) or placebo (n = 108) for 2-3 years. Patients were assessed every 3 months. The number of new ischemic digital ulcers was recorded as the primary end point, while the frequency of Raynaud's phenomenon episodes, skin score, health status, pulmonary artery pressure and treatments for ischemia were also monitored as secondary end points. There were no detectable differences between patients treated with quinapril and those receiving placebo; however, although no severe adverse effects were observed, patients taking quinapril experienced significantly more adverse effects. 相似文献
59.
Hypothalamitis: a diagnostic and therapeutic challenge 总被引:1,自引:0,他引:1
Antonio?BianchiEmail author Marilda?Mormando Francesco?Doglietto Linda?Tartaglione Serena?Piacentini Libero?Lauriola Giulio?Maira Laura?De Marinis 《Pituitary》2014,17(3):197-202
To report an unusual case of biopsy-proven autoimmune hypophysitis with predominant hypothalamic involvement associated with empty sella, panhypopituitarism, visual disturbances and antipituitary antibodies positivity. We present the history, physical findings, hormonal assay results, imaging, surgical findings and pathology at presentation, together with a 2-year follow-up. A literature review on the hypothalamic involvement of autoimmune hypophysitis with empty sella was performed. A 48-year-old woman presented with polyuria, polydipsia, asthenia, diarrhea and vomiting. The magnetic resonance imaging (MRI) revealed a clear suprasellar (hypothalamic) mass, while the pituitary gland appeared atrophic. Hormonal testing showed panhypopituitarism and hyperprolactinemia; visual field examination was normal. Pituitary serum antibodies were positive. Two months later an MRI documented a mild increase of the lesion. The patient underwent biopsy of the lesion via a transsphenoidal approach. Histological diagnosis was lymphocytic “hypothalamitis”. Despite 6 months of corticosteroid therapy, the patient developed bitemporal hemianopia and blurred vision, without radiological evidence of chiasm compression, suggesting autoimmune optic neuritis with uveitis. Immunosuppressive treatment with azathioprine was then instituted. Two months later, an MRI documented a striking reduction of the hypothalamic lesion and visual field examination showed a significant improvement. The lesion is stable at the 2-year follow-up. For the first time we demonstrated that “hypothalamitis” might be the possible evolution of an autoimmune hypophysitis, resulting in pituitary atrophy, secondary empty sella and panhypopituitarism. Although steroid treatment is advisable as a first line therapy, immunosuppressive therapy with azathioprine might be necessary to achieve disease control. 相似文献
60.